Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11218815 | 0.92 | LMNA (0.45) | LMNAMAPK1GABBR2GABBR1CYP2C19 | |
| SCHEMBL24177002 | 0.92 | OPRD1 (0.45) | LMNASLC6A9CYP2D6KDM4EATM | |
| SCHEMBL644556 | 0.78 | CYP2D6 (0.43) | LMNAMAPK1GABBR2GABBR1CYP2C19 | |
| SCHEMBL11077681 | 0.78 | CYP2D6 (0.43) | LMNAMAPK1GABBR2GABBR1CYP2C19 | |
| SCHEMBL11671946 | 0.78 | SRC (0.43) | LMNAMAPK1GABBR2GABBR1CYP2C19 | |
| SCHEMBL11588776 | 0.77 | GAA (0.50) | LMNAGABBR2GABBR1KDM4E | |
| SCHEMBL6727027 | 0.77 | TDP1 (0.48) | LMNAMAPK1GABBR2GABBR1CYP2C19 | |
| SCHEMBL10820763 | 0.76 | CYP2D6 (0.41) | LMNAMAPK1GABBR2GABBR1CYP2C19 | |
| SCHEMBL16153014 | 0.74 | OPRD1 (0.41) | LMNAMAPK1GABBR2GABBR1CYP2C19 | |
| SCHEMBL16656809 | 0.74 | ALOX5 (0.52) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165281-A1 | DUAL MODE RADIOTRACER AND THERAPEUTICS | UNIV MUENCHEN TECH (DE) | 2024-05-23 | — | — | US | claimed |
| EP-4337270-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2024-03-20 | — | — | EP | claimed |
| EP-4291250-A1 | DUAL MODE RADIOTRACER AND THERAPEUTICS | Technische Universität München (DE) | 2023-12-20 | — | — | EP | claimed |
| EP-4291252-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Technische Universität München (DE) | 2023-12-20 | — | — | EP | claimed |
| US-20230390394-A1 | Bismuth-Gadolinium Nanoparticles | NH THERAGUIX (FR) | 2023-12-07 | — | — | US | claimed |
| US-20230277698-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2023-09-07 | — | — | US | claimed |
| US-11559590-B2 | Granzyme B directed imaging and therapy | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-24 | — | — | US | claimed |
| US-20220175975-A1 | HER3 Peptides for Imaging and Radiotherapy | THE GENERAL HOSPITAL CORPORATION | 2022-06-09 | — | — | US | claimed |
| US-20220118120-A1 | CANCER DIAGNOSTIC IMAGING AGENTS | Technische Universität München (DE) | 2022-04-21 | — | — | US | claimed |
| US-11241511-B2 | HER3 peptides for imaging and radiotherapy | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-08 | — | — | US | claimed |
| EP-0752873-A1 | LABELLED PEPTIDE COMPOUNDS | MALLINCKRODT MEDICAL, INC. (US) | 1997-01-15 | — | — | EP | claimed |
| WO-1995022341-A1 | LABELLED PEPTIDE COMPOUNDS | MALLINCKRODT MEDICAL, INC. (US) | 1995-08-24 | — | — | WO | claimed |
| EP-0436005-B1 | LABELED POLYPEPTIDE DERIVATIVES | SANDOZ LTD (CH) | 1995-03-29 | — | — | EP | claimed |
| EP-0478631-B1 | TARGETTING AGENTS | CANCER RES CAMPAIGN TECH (GB) | 1994-08-24 | — | — | EP | claimed |
| EP-0584256-A1 | METHOD FOR DETECTING AN LOCALIZING TISSUES HAVING NEUROKININE 1 RECEPTORS | MALLINCKRODT MEDICAL, INC. (US) | 1994-03-02 | — | — | EP | claimed |
| WO-1992018536-A2 | METHOD FOR DETECTING AN LOCALIZING TISSUES HAVING NEUROKININE 1 RECEPTORS | MALLINCKRODT MEDICAL, INC. (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0498771-A2 | MSH peptide derivatives | SANDOZ LTD. (CH) | 1992-08-12 | — | — | EP | claimed |
| EP-0436005-A1 | LABELED POLYPEPTIDE DERIVATIVES. | SANDOZ LTD (CH) | 1991-07-10 | — | — | EP | claimed |
| WO-1991001144-A1 | LABELED POLYPEPTIDE DERIVATIVES | SANDOZ LTD (CH) | 1991-02-07 | — | — | WO | claimed |
| WO-1990006949-A2 | PEPTIDE DERIVATIVES | SANDOZ AG (CH) | 1990-06-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559590-B2 | Granzyme B directed imaging and therapy | GZMB, CTSB, PRF1 | LMNA 1420/4885MAPK1 3920/4885GABBR2 1340/4885 |
| US-20220175975-A1 | HER3 Peptides for Imaging and Radiotherapy | ERBB3, EGFR, NGLY1 | LMNA 4456/4885MAPK1 3082/4885GABBR2 4220/4885 |
| US-20230277698-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | KLK3, SHBG, SELPLG | LMNA 4022/4885MAPK1 2661/4885GABBR2 4017/4885 |
| US-20240165281-A1 | DUAL MODE RADIOTRACER AND THERAPEUTICS | FOLH1, KLK3, PAICS | LMNA 3949/4885MAPK1 1540/4885GABBR2 2853/4885 |
| US-11241511-B2 | HER3 peptides for imaging and radiotherapy | ERBB3, EGFR, NGLY1 | LMNA 4456/4885MAPK1 3082/4885GABBR2 4220/4885 |
| US-20230390394-A1 | Bismuth-Gadolinium Nanoparticles | BRCA1, GMNN, GNG2 | LMNA 1858/4885MAPK1 3255/4885GABBR2 1156/4885 |
| US-20220118120-A1 | CANCER DIAGNOSTIC IMAGING AGENTS | FOLH1, FOLR1, KLK3 | LMNA 3587/4885MAPK1 3975/4885GABBR2 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.